clinical trial · NCT03091192
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca·phase3·active not recruiting·n = 60
CarcinomaCarcinoma, Renal CellKidney NeoplasmsUrologic NeoplasmsKidney DiseasesNeoplasms by SiteEnzyme InhibitorsProtein Kinase InhibitorsSavolitinibSunitinib
brief summary
This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause.
started
Jul 25, 2017
primary completion
Aug 18, 2019
completion
Dec 31, 2026
last updated
Apr 14, 2026
official title
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol